TITLE

A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard

AUTHOR(S)
Schmucker, Christine; Ehlken, Christoph; Agostini, Hansjuergen T.; Antes, Gerd; Ruecker, Gerta; Lelgemann, Monika; Loke, Yoon K.
PUB. DATE
August 2012
SOURCE
PLoS Clinical Trials;Aug2012, Vol. 7 Issue 8, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. Methods and Findings: Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. We included RCTs with a minimum follow-up of one year which investigated bevacizumab or ranibizumab in direct comparison or against any other control group (indirect comparison). Direct comparison (3 trials, 1333 patients): The one year data show a significantly higher rate of ocular adverse effects (AE) with bevacizumab compared to ranibizumab (RR = 2.8; 95% CI 1.2–6.5). The proportion of patients with serious infections and gastrointestinal disorders was also higher with bevacizumab than with ranibizumab (RR = 1.3; 95% CI 1.0–1.7). Arterial thromboembolic events were equally distributed among the groups. Indirect comparison: Ranibizumab versus any control (5 trials, 4054 patients): The two year results of three landmark trials showed that while absolute rates of serious ocular AE were low (≤2.1%), relative harm was significantly raised (RR = 3.1; 95% CI 1.1–8.9). A significant increase in nonocular haemorrhage was also observed with ranibizumab (RR = 1.7; 95% CI 1.1–2.7). Bevacizumab versus any control (3 trials, 244 patients): We were unable to judge the safety profile of bevacizumab due to the poor quality of AE monitoring and reporting in the trials. Conclusions: Evidence from head-to-head trials raises concern about an increased risk of ocular and multiple systemic AE with bevacizumab. Therefore, clinicians and patients should continue to carefully weight up the benefits and harms when choosing between the two treatment options. We also emphasize the need for studies that are powered not just for efficacy, but for defined safety outcomes based on the signals detected in this systematic review.
ACCESSION #
88146234

 

Related Articles

  • Bevacizumab.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p23 

    The article describes cases of two patients, who experienced the rapid progression of subclinical age-related macular degeneration (AMD) in their untreated eyes. The patients, a 78-year-old woman and a 91-year-old man, received unilateral intravitreal bevacizumab for AMD. Details of the...

  • Bevacizumab.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p22 

    The article describes cases of sixteen patients who experienced local adverse events after receiving intravitreal bevacizumab 2.5 milligrams for treatment of their intraocular disease. The patients include two men, aged 80 and 81, who presented due to anterior chamber inflammation without...

  • Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. An, Mao; Zou, Zui; Shen, Hui; Liu, Ping; Chen, Meng; Cao, Yong; Jiang, Yuan // European Journal of Clinical Pharmacology;Aug2010, Vol. 66 Issue 8, p813 

    Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. The aim of this study was to gain a better understanding of the overall incidence and risk of significantly raised blood pressure in cancer patients who receive bevacizumab therapy. We performed a...

  • Drugs for older people: Proceed with caution. Lipman, Marvin M. // Consumer Reports on Health;Oct94, Vol. 6 Issue 10, p119 

    Presents information on the adverse effects of some drugs on older people. Physiological changes among the elderly; Danger of drug administration; Tips to ensure safety. INSET: Just say no..

  • The Epidemiology of Serious Adverse Drug Reactions Among the Elderly. Atkin, P.A.; Veitch, P.C.; Veitch, E.M.; Ogle, S.J. // Drugs & Aging;1999, Vol. 14 Issue 2, p141 

    Although the incidence and prevalence of serious adverse drug reactions (ADRs) in the elderly cannot be accurately stated, published estimates appear to be unchanged since the earliest reports in the 1960s. Whereas heightened awareness of the problem may weigh in favour of a reduction in ADR...

  • Epidemiology of Adverse Drug Reactions in the Elderly by Drug Class. Beyth, R.J.; Shorr, R.I. // Drugs & Aging;1999, Vol. 14 Issue 3, p231 

    As the growth of the elderly population continues, the burden on the health care system and society will also increase. Since chronic diseases such as hypertension, coronary artery disease, arthritis, stroke, cancer and diabetes mellitus are more prevalent with age, the number of people with...

  • Bevacizumab.  // Reactions Weekly;1/5/2013, Issue 1433, p12 

    The article cites a case of gastrointestinal perforation in an elderly patient receiving bevacizumab therapy.

  • Bevacizumab.  // Reactions Weekly;1/5/2013, Issue 1433, p12 

    The article describes the case of a 47-year-old man who developed osteonecrosis of the jaw and subsequently died while receiving treatment with bevacizumab.

  • Bevacizumab.  // Reactions Weekly;8/11/2012, Issue 1414, p15 

    The article describes two cases of pediatric patients who developed various toxicities while undergoing bevacizumab therapy for brain tumours.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics